EANS-News: Epigenomics CEO to give Corporate Update at Investor Conferences in Europe and U.S.
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Company Information/Molecular diagnostics
Press release, Berlin, Germany, and Seattle, WA, U.S.A., September 3, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company informed, that Geert W. Nygaard, CEO Epigenomics AG, will provide a corporate update at two upcoming Investor conferences in Zurich and New York.
At the German Healthcare Conference in Zurich and the UBS Global Life Sciences Conference in New York he will inform the investment community on the progress the Company made in commercializing its molecular diagnostic products for colon and lung cancer and provide an outlook on plans and activities regarding FDA clearance and commercialization of the Company's colorectal cancer blood test Epi proColon in the U.S.A.
Conference Details:
German Healthcare Conference Presentation on September 8, 2010 at 3:45 p.m. CET (9:45 a.m. EDT), Zurich, Switzerland
UBS Global Life Sciences Conference Presentation on September 20, 2010, at 7:30 a.m. EDT (1:30 p.m. CET), New York, U.S.A.
The presentation will be available for download on Epigenomics website: http://www.epigenomics.com/en/down_loads/corporate_material/
For further question please contact:
Dr. Achim Plum Sen. VP. Corporate Development Tel. +49 30 24 34 5 386 achim.plum@epigenomics.com
About Epigenomics
Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests on the market and in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.
Epigenomics' product portfolio contains the CE-marked IVD test Epi
proColon, the world's first regulatory cleared molecular diagnostic
test for the detection of colorectal cancer in blood that is based on
the biomarker Septin9, and further proprietary DNA methylation
biomarkers and IVD products at various stages of development for
colorectal, lung and prostate cancer. For development and global
commercialization of IVD test products, Epigenomics pursues a dual
business strategy in which direct commercialization of proprietary
diagnostic test products is combined with non-exclusive licensing to
diagnostic industry players with broad customer access. Strategic
diagnostics industry partners include Abbott Molecular, Sysmex
Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories,
Inc. for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary,
Epigenomics Inc., in Seattle, WA, USA. For more information, please
visit Epigenomics' website at {www.epigenomics.com}[HYPERLINK:
http://www.epigenomics.com/].Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States of America. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the USA have not been established.
end of announcement euro adhoc
Further inquiry note:
Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com
Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade